Investment Rating - The report assigns a "Buy" rating to Ximei Resources Holding Limited with a target price of HKD 12.35 based on a 16x PE for 2026 [3]. Core Insights - Ximei Resources is a leading player in the tantalum and niobium industries in China, focusing on green development and the extension of its industrial chain [1]. - The company has achieved significant growth in its core departments, with a notable increase in revenue and net profit in the first half of 2025 [4]. - The company is actively enhancing its production capacity and optimizing its product structure to meet market demands [35]. Financial Data and Forecast - Revenue projections for 2024 to 2027 are as follows: - 2024: CNY 1,822 million - 2025: CNY 1,955 million (30% YoY growth) - 2026: CNY 2,282 million (17% YoY growth) - 2027: CNY 2,542 million (11% YoY growth) [4] - Net profit forecasts for the same period are: - 2024: CNY 124 million - 2025: CNY 197 million (59% YoY growth) - 2026: CNY 267 million (36% YoY growth) - 2027: CNY 369 million (38% YoY growth) [4]. Company Overview - Ximei Resources is a prominent producer of tantalum and niobium metallurgical products, with a focus on high-purity tantalum and niobium compounds essential for high-tech industries [8]. - The company has a significant market share in the domestic wet-process products, accounting for approximately 40% of the market [8]. - The company aims to become a world-leading manufacturer in the tantalum and niobium sector, with a strong emphasis on technological innovation and sustainable practices [34]. Industry Dynamics - The global distribution of tantalum and niobium resources is uneven, with major reserves located in Australia and Brazil [13][19]. - China's tantalum and niobium resources are limited, with domestic production meeting only a small fraction of its industrial needs, leading to high import dependency [19]. - The demand for tantalum and niobium is expected to grow significantly due to their applications in electronics, aerospace, and other high-tech fields [20][24]. Project Development - The Leizhou project is a key initiative for Ximei Resources, aiming to produce 3,000 tons of high-performance tantalum and niobium oxides annually, utilizing advanced wet-process metallurgy [37]. - The project is designed to enhance the company's production capabilities and support sustainable development in the tantalum and niobium industry [37].

Investment Rating - The investment rating for the company is "Buy" [4] Core Insights - The company's core products have successfully been included in the 2025 National Medical Insurance Drug List, which is expected to drive sales growth [1][3] - The clinical data for the PD-1/VEGF bispecific antibody RC148 shows promising efficacy and safety in treating non-small cell lung cancer, indicating a significant clinical advantage [2][4] - The management team is experienced, and the company has a strong R&D capability, with a stable pipeline of clinical indications [8] Summary by Sections Event 1 - Two innovative drugs from the company have been successfully included in the 2025 National Medical Insurance Drug List, with one new indication for 泰爱® (Tai'ai) and three renewed indications for both 泰爱® and 爱地希® (Aidiqi) [1] Event 2 - The clinical research data for RC148 in treating non-small cell lung cancer has been disclosed, showing outstanding clinical efficacy and manageable safety [2] Clinical Data - The clinical trial results for RC148 indicate an objective response rate (ORR) of 61.9% for monotherapy and 66.7% for combination therapy, with a disease control rate (DCR) of 100% and 95.2% respectively [4] Financial Projections - Revenue projections for 2025-2027 are adjusted to 27.52 billion, 33.85 billion, and 44.13 billion yuan, reflecting year-on-year growth rates of 60.95%, 22.97%, and 30.40% respectively [8] - The net profit for the same period is projected to improve significantly, with estimates of -7.63 billion, -3.16 billion, and 3.84 billion yuan [8]

Investment Rating - The report assigns a "Buy" rating with a target price of HKD 28.35 per share, indicating a potential upside of 26% from the current price of HKD 22.50 [5][15]. Core Insights - The company is a leader in the domestic neurovascular and peripheral vascular interventional medical device sector, demonstrating high research and development efficiency with a diverse product line of 73 items, of which 51 are commercialized in China [4][7]. - The company has achieved significant international expansion, with revenue from international markets reaching RMB 15.7 million in the first half of 2025, a year-on-year increase of 36.9% [3][9]. - The company reported a total operating revenue of RMB 482 million for the first half of 2025, representing a year-on-year growth of 31.69%, driven by strong sales in neurovascular and peripheral vascular interventional devices [4][12]. Summary by Sections Investment Highlights - The company has a robust R&D platform that has successfully launched several innovative products, including the Qilin blood flow guiding device and OCT-guided peripheral vascular plaque directional cutting guiding catheter series [4][7]. - The company is actively expanding its international presence, with 22 products commercialized in 27 countries and entering 7 of the top 10 global markets [3][9]. - The company’s revenue growth is supported by the strong performance of its neurovascular and peripheral vascular interventional devices, with neurovascular product sales reaching RMB 304 million, accounting for 63.3% of total revenue [4][12]. Financial Projections - Revenue projections for 2025-2027 are RMB 1.056 billion, RMB 1.377 billion, and RMB 1.797 billion, respectively, with net profits expected to be RMB 223 million, RMB 309 million, and RMB 389 million [5][15]. - The company’s net profit margin is projected to improve significantly, with a forecasted net profit growth of 122.5% in 2025 and 38.6% in 2026 [6][15]. Market Position - The company is well-positioned in the market due to its competitive advantages in domestic substitution and continuous investment in R&D [5][15]. - The optimization of centralized procurement policies by the healthcare authority is expected to further enhance the company's future performance [4][12].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a strong expectation of performance relative to the market [4]. Core Insights - The company is focusing on a dual-driven strategy of organic growth and acquisitions, with a particular emphasis on three major strategic areas: Super Brand, Super Chain, and Super Digitalization [6]. - The acquisition of 100% of the shares of Siyanli for 1.25 billion RMB (approximately 1.369 billion HKD) is expected to enhance market share and accelerate the company's strategic layout [4]. - The company has increased its stake in Nairui to 90%, with significant improvements in operational efficiency post-acquisition, reflected in a rise in adjusted net profit margin from 6.5% to 10.4% [5]. Financial Data and Earnings Forecast - The company forecasts revenue growth from 2,145 million RMB in 2023 to 4,541 million RMB in 2027, with a compound annual growth rate (CAGR) of approximately 31.16% [8]. - Adjusted net profit is projected to increase from 241 million RMB in 2023 to 540 million RMB in 2027, with a notable growth rate of 53.18% in 2023 [8]. - The adjusted earnings per share (EPS) is expected to rise from 1.05 RMB in 2023 to 2.29 RMB in 2027, reflecting a strong upward trend in profitability [8].

Investment Rating - The investment rating for the company is "Buy" [4] Core Insights - The company has successfully included three core products in the national medical insurance directory, enhancing accessibility for patients [1][3] - A collaboration with Crescent Biopharma aims to develop and commercialize new cancer treatment methods, focusing on ADC and dual-specific antibodies [2][7] - The company is expected to see significant revenue growth due to the successful inclusion of its products in the national insurance scheme and its strong R&D capabilities [8] Summary by Sections Event 1 - The company's three core products, including ADC Sacituzumab Tirumotecan, have been included in the national medical insurance directory, with two indications for the ADC product [1] - This inclusion is expected to improve patient access and benefit a larger clinical population [3] Event 2 - The partnership with Crescent Biopharma will facilitate the development of SKB105 and CR-001, targeting ITGB6 and PD-1xVEGF respectively [2] - The collaboration includes rights for independent development of combination therapies, enhancing the company's pipeline [2][7] Analyst Commentary - The successful inclusion of the ADC product in the insurance directory showcases its clinical potential and market viability [3] - The company is actively expanding its international clinical collaborations, which is expected to bolster cash flow and explore new treatment combinations [7] Financial Projections - Revenue forecasts for 2025-2027 are adjusted to 21.75 billion, 29.12 billion, and 49.23 billion respectively, with year-on-year growth rates of 12.52%, 33.89%, and 69.06% [8][10] - The company is projected to achieve profitability by 2027, with a net profit of 790.85 million [10][12]

Investment Rating - The report assigns a rating of "Buy" for CITIC Financial Assets [6]. Core Views - The company has established a new business pattern focusing on non-performing asset management and long-term equity investment, with the latter becoming a new stabilizing force for performance [2]. - The report highlights the ongoing transformation in non-performing asset management and the strategic shift towards long-term equity investments as a counter-cyclical measure [10]. Financial Summary - Total revenue is projected to reach RMB 62,183.98 million in 2025, with a growth rate of 142.8% in 2024, followed by a decline of 11.9% in 2025 [4]. - Net profit is expected to increase significantly, reaching RMB 9,618.37 million in 2025, reflecting a growth of 444.6% from the previous year [4]. - The report provides a price-to-earnings (PE) ratio of 7.42 for 2025 and a price-to-book (PB) ratio of 1.63 for the same year [4]. Business Analysis - The company is one of the four major Asset Management Companies (AMCs) in China, with a focus on non-performing asset management as its core business [31]. - The report indicates that the company is undergoing structural adjustments in its non-performing asset management, with a cautious approach to risk recognition [57]. - Long-term equity investments are highlighted as a new stabilizing factor, providing steady returns and long-term value [10][57]. Earnings Forecast and Valuation - The forecast predicts a net profit growth of 7.4% in 2025, 11.0% in 2026, and 8.6% in 2027, reaching RMB 12,451.52 million by 2027 [10]. - The report sets a target price of HKD 1.16 based on a 2x PB valuation for 2025 [10].

Investment Rating - The report gives a "Buy" rating for the company, Minth Group [1]. Core Views - The company is positioned as a global leader in automotive exterior and structural components, focusing on electric vehicle (EV) battery boxes and expanding into humanoid robotics and liquid cooling technologies, which are expected to drive future growth [8][13]. Summary by Sections Company Overview - Minth Group is a globally recognized supplier of automotive exterior and structural components, with a product system based on various new materials and surface treatment technologies. The company has established four major product lines and is heavily investing in the electric vehicle sector, becoming the largest supplier of battery boxes and structural components [8][13]. Battery Box Business Development - The battery box is a critical component for electric vehicle battery modules, and its market is expected to grow significantly as EV penetration increases. The report estimates that the Chinese battery box market will reach 31.8 billion yuan in 2024 and 78.2 billion yuan by 2030, while the European market is projected to grow from 9.4 billion yuan in 2024 to 29.9 billion yuan by 2030 [8][45][47]. Robotics and Liquid Cooling - Minth is leveraging its automotive manufacturing expertise to enter the humanoid robotics sector, focusing on integrated joint modules and other robotic components. Additionally, the company is making strides in the AI liquid cooling market, driven by increasing energy efficiency requirements and partnerships with leading server manufacturers [8][18]. Financial Forecast and Valuation - The company is projected to achieve net profits of 2.75 billion yuan, 3.26 billion yuan, and 3.88 billion yuan for the years 2025 to 2027, respectively. The earnings per share (EPS) are expected to be 2.34 yuan, 2.76 yuan, and 3.29 yuan for the same period, with corresponding price-to-earnings (P/E) ratios of 11.91, 10.07, and 8.46 [1][8].

Investment Rating - The report maintains a "Buy" rating for Xiaomi Group (1810.HK) [5][7]. Core Insights - Xiaomi's AI strategy is characterized as a long-distance race rather than a sprint, with significant investments planned for the next five years, exceeding 200 billion RMB [5]. - The newly released Mimo-V2-Flash model demonstrates industry-leading performance with a lightweight design featuring 309 billion total parameters and 15 billion activation parameters, outperforming competitors in key metrics [2]. - Xiaomi has established the largest consumer hardware platform globally, with 1.8 billion connected devices, including 740 million active mobile users and over 1 billion IoT devices, which provides a robust foundation for AI technology deployment [3]. Summary by Sections AI Model Development - The Mimo-V2-Flash model achieves a 2.0 to 2.6 times increase in inference speed and has a throughput of 5000-15000 tokens per second, significantly enhancing efficiency and cost-effectiveness for large-scale AI applications [2]. - The model is fully open-sourced, with APIs and web experiences available, aiming to attract global developers and create a positive feedback loop for model iteration [2]. Hardware Ecosystem - Xiaomi's hardware ecosystem includes 1.8 billion connected devices, with a focus on personal, automotive, and home devices, which enhances the potential for AI technology applications [3]. Software Infrastructure - The upcoming release of the Pengpai OS 3 in August 2025 will enhance ecosystem collaboration, supporting over 60 applications and 70 scenarios, with a daily active user base of 410 million [4]. - The Vela lightweight system and MINT platform are designed to facilitate AI deployment across various devices, with over 100 open-source partners contributing to the ecosystem [4]. Financial Projections - Revenue projections for Xiaomi indicate a growth trajectory, with expected revenues of 270.97 billion RMB in 2023, increasing to 635.31 billion RMB by 2027, and Non-IFRS net profits projected to rise from 19.27 billion RMB in 2023 to 50.97 billion RMB in 2027 [6][26]. - The report anticipates a significant increase in Non-IFRS earnings per share, from 0.77 RMB in 2023 to 1.96 RMB in 2027, reflecting strong profitability growth [6][26].

Investment Rating - The report maintains a "Buy" rating for Tencent Holdings (00700.HK) with a current price of 605.00 HKD and a fair value of 754.73 HKD [10]. Core Insights - Tencent Cloud is leveraging its domestic advantages to expand its overseas business, particularly in Southeast Asia and the Middle East, with a focus on stable energy and power supply for data centers [10][12]. - The company has developed a comprehensive AI strategy, integrating AI into its business model and enhancing talent acquisition, which is expected to accelerate growth [10][16]. - The financial forecast remains unchanged, with projected revenues of 7,524 billion RMB and 8,278 billion RMB for 2025 and 2026, respectively, reflecting growth rates of 14.0% and 10.0% [10][25]. Financial Projections - Revenue (in billion RMB): - 2023A: 6,090 - 2024A: 6,603 - 2025E: 7,524 - 2026E: 8,278 - 2027E: 8,915 - EBITDA (in billion RMB): - 2023A: 2,119 - 2024A: 2,941 - 2025E: 3,022 - 2026E: 3,528 - 2027E: 3,991 - Net profit attributable to shareholders (in billion RMB): - 2023A: 1,577 - 2024A: 2,227 - 2025E: 2,586 - 2026E: 2,953 - 2027E: 3,295 - EPS (in RMB/share): - 2023A: 16.32 - 2024A: 23.51 - 2025E: 28.32 - 2026E: 32.34 - 2027E: 36.09 - P/E Ratio: - 2023A: 16.3 - 2024A: 16.1 - 2025E: 19.4 - 2026E: 17.0 - 2027E: 15.2 - ROE (%): - 2023A: 19.5% - 2024A: 22.9% - 2025E: 22.4% - 2026E: 21.7% - 2027E: 20.8% [4][10]. Tencent Cloud Expansion - Tencent Cloud has established infrastructure in 22 physical regions and 64 availability zones globally, with over 3,200 acceleration nodes, focusing on Southeast Asia and the Middle East for future growth [12][10]. - The strategy for acquiring core customers in Southeast Asia includes deepening relationships with local leading enterprises and serving Chinese companies expanding overseas [13][10]. AI Integration - Tencent's AI strategy encompasses infrastructure, platform tools, and application layers, with significant investments in talent acquisition to enhance AI capabilities [16][10]. - AI is expected to drive growth in advertising and gaming sectors, with improvements in user experience and operational efficiency [17][10].

证券研究报告 非银金融 | 保险Ⅱ 港股|首次覆盖报告 hyzqdatemark 2025 年 12 月 18 日 证券分析师 陆韵婷 SAC：S1350525050002 luyunting@huayuanstock.com 沈晨 SAC：S1350525090002 shenchen@huayuanstock.com 市场表现： | 基本数据 | 2025 | 年 | 12 | 月 17 | 日 | | --- | --- | --- | --- | --- | --- | | 收盘价（港元） | | | | 3.21 | | | 一年内最高/最低（港 | | | | 7.36/0.87 | | | 元） | | | | | | | 总市值（百万港元） | | | | 13,030.33 | | | 流通市值（百万港元） | | | | 13,030.33 | | | 资产负债率（%） | | | | 84.60 | | | 资料来源：聚源数据 | | | | | | 云锋金融(00376.HK) 投资评级： 买入（首次） ——新业务价值高增，投资管理能力独特 投资要点： 联系人 扎根香港寿险市场，兼具强 ...